Jarred Reed
Internal Medicine · Los Angeles, CANPI 1013250869
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (52.2%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by AstraZeneca at 55.5% of the total. Reporting peaked in 2024 at $2,945 and has fallen 71.4% since, to $842 in 2025. Among internal medicine clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 89 payments — averaging $56.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Regeneron$350
- Bristol Myers Squibb$262
- Genentech USA, Inc.$222
- Lilly USA, LLC$162
- Seagen Inc.$161
- plus $1K from 26 others
What the payments were for
- Consulting fees$2,62552%
- Speaking & faculty fees$3507%
- Food & beverage$1,89938%
- Education$1583%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 13 | $2,793 |
| Regeneron | 1 | $350 |
| Bristol Myers Squibb | 10 | $262 |
| Genentech USA, Inc. | 6 | $222 |
| Lilly USA, LLC | 3 | $162 |
| Seagen Inc. | 8 | $161 |
| Regeneron Healthcare Solutions, Inc. | 4 | $120 |
| Johnson & Johnson(2 entities) | 5 | $110 |
| Incyte Corporation | 4 | $90 |
| AbbVie | 3 | $71 |
| E.r. Squibb & Sons, L.L.C. | 3 | $58 |
| Pfizer | 3 | $54 |
| ADC Therapeutics America, Inc. | 2 | $50 |
| Sanofi | 2 | $46 |
| Gilead | 2 | $44 |
| Eisai Inc. | 2 | $40 |
| Bayer | 2 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $35 |
| Dendreon Pharmaceuticals LLC | 1 | $30 |
| Immunogen, Inc. | 1 | $29 |
| Amgen | 1 | $29 |
| Tersera Therapeutics LLC | 1 | $29 |
| Merck | 1 | $28 |
| Ipsen Biopharmaceuticals, Inc | 1 | $26 |
| Mirati Therapeutics, Inc. | 1 | $24 |
| Lexicon Pharmaceuticals, Inc. | 1 | $23 |
| Stemline Therapeutics Inc. | 1 | $22 |
| Puma Biotechnology, Inc. | 1 | $20 |
| Array Biopharma Inc | 1 | $18 |
| Agios Pharmaceuticals, Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Foundation Medicine, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,032 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Los Angeles
- William HardyLos Angeles$704K
- Soha DolatabadiLos Angeles$458K
- Matthew HerrmannLos Angeles$384K
- Koppany VisnyeiLos Angeles$287K
- Jaime BetancourtLos Angeles$286K
- William KingLos Angeles$227K
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.